Bionano Genomics(US:BNGO) Financial Modeling Prep·2026-03-20 20:00Core Viewpoint - Bionano Genomics, Inc. is a life sciences company focused on genome analysis, providing essential tools and services for genetic research, which are vital for understanding genetic diseases and developing treatments [1] Financial Performance - Bionano is set to release its quarterly earnings on March 23, 2026, with Wall Street estimating a loss of $2.47 per share and analysts predicting a smaller loss of $1.40 per share [2][6] - Revenue projections are closely aligned, with Wall Street expecting $7.88 million and analysts estimating $7.85 million, while the company previously projected revenue between $7.8 million and $8.0 million [2] Stock Valuation - The current stock price of Bionano is $1.12, with a negative price-to-earnings (P/E) ratio of -0.16 and a price-to-sales ratio of 0.13, indicating the stock is valued at 13 cents for every dollar of sales [3][6] - The enterprise value to sales ratio is 0.28, reflecting the company's valuation relative to its revenue [3] Financial Health Indicators - The enterprise value to operating cash flow ratio is around -0.43, indicating negative cash flow [4] - The debt-to-equity ratio is 0.15, suggesting low debt levels, while the current ratio of 2.12 indicates good short-term financial health, with more than twice the current assets compared to liabilities [4][6] Analyst Ratings - Analyst Yi Chen from HC Wainwright and Co. maintains a Buy rating on Bionano, although the price target was reduced from $11 to $7 in November 2025 [5] - Bionano will host a conference call and webcast on March 23, 2026, to discuss its financial results and corporate progress, with CEO Erik Holmlin participating [5]